Severe tricuspid regurgitation is now widely thought of as a significant contributor to cardiac morbidity and mortality. Neither medical therapy nor conventional surgery is efficacious for most patients. In contrast, with the rapid development of transcatheter tricuspid valve therapies, tricuspid regurgitation can now be corrected without incurring the risks of conventional surgery, and it is showing promise to improve quality of life and mortality. We will talk about transcatheter tricuspid valve interventions, the current status of clinical trials in the United States, transcatheter tricuspid valve intervention devices we have used, and our experience.

Educated in Japan, Tadahisa Sugiura attended University of Tsukuba School of Medicine, earning his Doctor of Medicine degree in 2003. He has completed Cardiothoracic surgery training in Japan. Dr. Sugiura came to the United States in 2013 and continued his training. He became an Attending surgeon and Assistant Professor at Montefiore Medical Center/Albert Einstein College of Medicine in 2019. His clinical focus is in structural heart disease, the treatment of end-stage heart failure, extracorporeal membrane oxygenation (ECMO). He has shared his research through publication in many peer-reviewed journals, book chapters, abstracts, posters and presentations. Dr. Sugiura is a member of several professional societies including the Society of Thoracic Surgeons, the Japanese Society for Thoracic Surgery, and the Japanese Society for Cardiovascular Surgery.